타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Platinum Based Chemotherapy (Platinum Based Chemotherapy) Merck Sharp & Dohme LLC·Ovarian Cancer 128 trials | |
|---|---|---|
Overview Program | Platinum Based Chemotherapy | HWK-007 |
Overview Company | Merck Sharp & Dohme LLC | Whitehawk Therapeutics, Inc. |
Overview Modality | ADC | ADC |
Overview Target | Ovarian Cancer | EGFR |
Overview Indication | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R | Endometrial Cancer; Ovarian Cancer |
Overview Phase | PHASE_3 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational |
Technology Payload | vedotin (ARON-2EV study) | — |
MoA Mechanism | targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling | — |
MoA Biomarker | biomarker-embedded clinical trials, molecular subtype-stratified patient selection, and rigorous evaluation o | — |
Clinical Program phase | PHASE_3 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Platinum Based Chemotherapy (Platinum Based Chemotherapy) Merck Sharp & Dohme LLC·Ovarian Cancer 128 trials | |
|---|---|---|
Overview Program | Platinum Based Chemotherapy | HWK-007 |
Overview Company | Merck Sharp & Dohme LLC | Whitehawk Therapeutics, Inc. |
Overview Modality | ADC | ADC |
Overview Target | Ovarian Cancer | EGFR |
Overview Indication | Nonsquamous Non-small Cell Lung Cancer; EGFR L858R | Endometrial Cancer; Ovarian Cancer |
Overview Phase | PHASE_3 | PHASE_1 |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging | Development Signal · Watch |
Overview Approval status | Investigational | Investigational |
Technology Payload | vedotin (ARON-2EV study) | — |
MoA Mechanism | targeting oxidative stress, hypoxia, persistent DNA damage, immune signaling | — |
MoA Biomarker | biomarker-embedded clinical trials, molecular subtype-stratified patient selection, and rigorous evaluation o | — |
Clinical Program phase | PHASE_3 | PHASE_1 |
Clinical Trial activity | No active/completed counts | — |
추천 비교
추천 비교